ATE470454T1 - Multimere konstrukte - Google Patents

Multimere konstrukte

Info

Publication number: ATE470454T1
Authority: AT; Austria
Prior art keywords: fusion proteins; domain; flt; multimerization; neovascularization
Prior art date: 2004-09-13

Application number

AT05810409T

Other languages

English (en)

Inventor

Abraham Scaria

Peter Pechan

Samuel Wadsworth

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-13

Filing date

2005-09-13

Publication date

2010-06-15

2005-09-13 Application filed by Genzyme Corp filed Critical Genzyme Corp

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE470454T1 publication Critical patent/ATE470454T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Wood Science & Technology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)

AT05810409T 2004-09-13 2005-09-13 Multimere konstrukte ATE470454T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US60888704P	2004-09-13	2004-09-13
US65820905P	2005-03-04	2005-03-04
PCT/US2005/032320 WO2006031689A2 (en)	2004-09-13	2005-09-13	Multimeric constructs

Publications (1)

Publication Number	Publication Date
ATE470454T1 true ATE470454T1 (de)	2010-06-15

Family

ID=36060586

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05810409T ATE470454T1 (de)	2004-09-13	2005-09-13	Multimere konstrukte

Country Status (16)

Country	Link
US (4)	US7928072B2 (de)
EP (2)	EP1804835B9 (de)
JP (1)	JP4944032B2 (de)
CN (1)	CN101094688B (de)
AT (1)	ATE470454T1 (de)
BR (1)	BRPI0515264B1 (de)
CY (1)	CY1114155T1 (de)
DE (1)	DE602005021811D1 (de)
DK (2)	DK1804835T3 (de)
ES (2)	ES2407859T3 (de)
HK (1)	HK1144663A1 (de)
IL (2)	IL181839A0 (de)
MX (1)	MX2007002942A (de)
PL (2)	PL1804835T3 (de)
PT (2)	PT1804835E (de)
WO (1)	WO2006031689A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2407859T3 (es) *	2004-09-13	2013-06-14	Genzyme Corporation	Construcciones multiméricas.
WO2009042162A2 (en) *	2007-09-25	2009-04-02	Genzyme Corporation	Compositions and methods for inhibiting interleukin pathways
CN101951925A (zh) *	2008-02-20	2011-01-19	建新公司	血管发生抑制
WO2010019263A2 (en) *	2008-08-15	2010-02-18	Genzyme Corporation	Soluble flt constructs for treating cancers
US8697654B2 (en) *	2008-12-18	2014-04-15	E I Du Pont De Nemours And Company	Peptide linkers for effective multivalent peptide binding
LT2601214T (lt)	2010-08-06	2018-02-26	Genzyme Corporation	Vegf antagonistų kompozicijos ir jų panaudojimas
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
DK3357511T3 (da)	2011-06-30	2020-08-03	Genzyme Corp	Inhibitorer af t-celleaktivering
WO2013028541A1 (en) *	2011-08-19	2013-02-28	Children's Medical Center Corporation	Vegf-binding protein for blockade of angiogenesis
CN102399292A (zh) *	2011-09-14	2012-04-04	盛剑鹏	重组干细胞因子与免疫球融合蛋白及其制备
US20130090375A1 (en) *	2011-10-06	2013-04-11	Cornell University	Virus-mediated delivery of bevacizumab for therapeutic applications
CN104271590B (zh)	2012-01-24	2018-06-05	Inter-K私人有限公司	用于癌治疗的肽剂
WO2013163419A1 (en) *	2012-04-25	2013-10-31	Ligacept Llc	Broad spectrum erbb ligand binding molecules and methods for their use
TWI775096B (zh)	2012-05-15	2022-08-21	澳大利亞商艾佛蘭屈澳洲私營有限公司	使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2867254B1 (de) *	2012-06-27	2017-10-25	F. Hoffmann-La Roche AG	Verfahren zum herstellen von antikörper-fc-region-konjugaten mit mindestens einer bindungsstelle, die spezifisch an ein target bindet, und verwendungen davon
ES2597228T3 (es)	2012-06-27	2017-01-17	F. Hoffmann-La Roche Ag	Procedimiento para la selección y la producción de entidades de objetivación, como dianas, altamente selectivas y multiespecíficas, personalizadas, las cuales contienen por lo menos dos entidades de unión diferentes, y utilización de éstas
SI2968461T1 (sl)	2013-03-13	2023-01-31	Genzyme Corporation	Fuzijski proteini, ki vsebujejo vezavna dela PDGF in VEGF in postopek njihove uporabe
KR102049990B1 (ko)	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
BR112016017817A2 (pt) *	2014-02-06	2017-10-10	Genzyme Corp	composições e métodos para o tratamento e a prevenção de degeneração macular
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
GB201412748D0 (en) *	2014-07-17	2014-09-03	Levicept Ltd	Therapeutic use of P75NTR neurotrophin binding protein
EP3253797A4 (de) *	2015-02-03	2018-10-03	Jyant Technologies, Inc.	Chemokin-immunoglobulin-fusionspolypeptide, zusammensetzungen daraus, verfahren zur herstellung und verwendung davon
IL260323B2 (en)	2015-12-30	2025-01-01	Kodiak Sciences Inc	Antibodies and their conjugates
KR102205830B1 (ko) *	2017-10-26	2021-01-21	주식회사 큐로진생명과학	솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물
KR20200140817A (ko)	2018-03-02	2020-12-16	코디악 사이언시스 인코포레이티드	Il-6 항체 그리고 이의 융합 작제물 및 접합체
US20220214340A1 (en) *	2019-04-28	2022-07-07	Leide Biosciences Co., Ltd.	Zipper structure that helps the formation of protein dimer and application thereof
CN114786731A (zh)	2019-10-10	2022-07-22	科达制药股份有限公司	治疗眼部病症的方法
CA3182893A1 (en)	2020-05-08	2021-11-11	Regeneron Pharmaceuticals, Inc.	Vegf traps and mini-traps and methods for treating ocular disorders and cancer
CN116370335A (zh) *	2021-12-31	2023-07-04	康码（上海）生物科技有限公司	用于擦拭的病毒防护溶液以及病毒防护擦拭产品
WO2024029876A1 (ko)	2022-08-02	2024-02-08	주식회사 파노로스바이오사이언스	변형된 융합 단백질 및 이의 용도

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
US5567584A (en)	1988-01-22	1996-10-22	Zymogenetics, Inc.	Methods of using biologically active dimerized polypeptide fusions to detect PDGF
ES2092468T3 (es)	1988-01-22	1996-12-01	Zymogenetics Inc	Metodos para producir analogos de receptores secretados.
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
JPH03233530A (ja)	1990-02-09	1991-10-17	Fuji Photo Optical Co Ltd	カメラ
US5670488A (en)	1992-12-03	1997-09-23	Genzyme Corporation	Adenovirus vector for gene therapy
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
US20020032313A1 (en)	1991-03-29	2002-03-14	Genentech, Inc.	Vascular endothelial cell growth factor antagonists
EP1167384B1 (de)	1992-10-28	2006-12-13	Genentech, Inc.	HVEGF Rezeptor als VEGF Antagonist
FR2702152B1 (fr)	1993-03-03	1995-05-24	Inst Nat Sante Rech Med	Virus recombinants et leur utilisation en thérapie génique.
JP3734262B2 (ja)	1993-03-25	2006-01-11	メルクエンドカンパニーインコーポレーテッド	血管内皮細胞増殖因子阻害剤
DE69434447T2 (de)	1993-06-07	2006-05-18	Vical, Inc., San Diego	Für die gentherapie verwendbare plasmide
US5919676A (en)	1993-06-24	1999-07-06	Advec, Inc.	Adenoviral vector system comprising Cre-loxP recombination
US6686200B1 (en)	1993-08-31	2004-02-03	Uab Research Foundation	Methods and compositions for the large scale production of recombinant adeno-associated virus
WO1995029993A1 (en)	1994-04-28	1995-11-09	The University Of Michigan	Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line
US5827702A (en)	1994-10-31	1998-10-27	Genentech, Inc.	Ocular gene therapy
US5650096A (en)	1994-12-09	1997-07-22	Genzyme Corporation	Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948767A (en)	1994-12-09	1999-09-07	Genzyme Corporation	Cationic amphiphile/DNA complexes
US5939401A (en)	1994-12-09	1999-08-17	Genzyme Corporation	Cationic amphiphile compositions for intracellular delivery of therapeutic molecules
US5719131A (en)	1994-12-09	1998-02-17	Genzyme Corporation	Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5910487A (en)	1994-12-09	1999-06-08	Genzyme Corporation	Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules
US5767099A (en)	1994-12-09	1998-06-16	Genzyme Corporation	Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US5840710A (en)	1994-12-09	1998-11-24	Genzyme Corporation	Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules
US5747471A (en)	1994-12-09	1998-05-05	Genzyme Corporation	Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules
EP0821739B1 (de)	1995-04-17	2003-06-18	The Board Of Regents, The University Of Texas System	Adenovirus helfervirus system
ATE445705T1 (de)	1995-06-15	2009-10-15	Crucell Holland Bv	Verpackungssysteme für humane rekombinante adenoviren zur gentherapie
US6013516A (en)	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
JPH09154588A (ja)	1995-10-07	1997-06-17	Toagosei Co Ltd	Ｖｅｇｆ結合性ポリペプチド
US6156497A (en)	1996-01-05	2000-12-05	Genetic Therapy, Inc.	Recombinase-mediated generation of adenoviral vectors
US5994317A (en)	1996-04-09	1999-11-30	Vical Incorporated	Quaternary cytofectins
US6100071A (en) *	1996-05-07	2000-08-08	Genentech, Inc.	Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US5935936A (en)	1996-06-03	1999-08-10	Genzyme Corporation	Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules
DE69736860T2 (de)	1996-09-24	2007-05-16	Merck & Co., Inc.	Verbindungen zur hemmung der angiogenese durch gentherapie
US5861397A (en)	1996-10-03	1999-01-19	Vical Incorporated	Piperazine based cytofectins
WO1998031794A1 (fr)	1997-01-17	1998-07-23	Toa Gosei Co., Ltd.	Polypeptide liant le facteur vegf
US5925628A (en)	1997-03-31	1999-07-20	Genzyme Corporation	Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5912239A (en)	1997-04-04	1999-06-15	Genzyme Corporation	Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules
US5948925A (en)	1997-05-06	1999-09-07	Genzyme Corporation	Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids
US5942634A (en)	1997-05-09	1999-08-24	Genzyme Corporation	Cationic amphiphiles for cell transfections
AU7383298A (en)	1997-05-13	1998-12-08	Regents Of The University Of California, The	Novel antiangiogenic peptide agents and their therapeutic and diagnostic use
US5952916A (en)	1998-05-28	1999-09-14	Atras Auto Co., Ltd	Hammer-equipped emergency signal device
DE69832798T2 (de)	1997-06-03	2006-09-14	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen.
CA2293723A1 (en)	1997-06-18	1998-12-23	Merck & Co., Inc.	Human receptor tyrosine kinase, kdr
US5963622A (en)	1997-07-29	1999-10-05	3Com Corporation	Mode signalling method and apparatus
WO1999014354A1 (en)	1997-09-19	1999-03-25	The Trustees Of The University Of The Pennsylvania	Methods and vector constructs useful for production of recombinant aav
US5994136A (en)	1997-12-12	1999-11-30	Cell Genesys, Inc.	Method and means for producing high titer, safe, recombinant lentivirus vectors
WO1999057296A1 (en)	1998-05-01	1999-11-11	Genzyme Corporation	Partially deleted adenoviral vectors
US6378526B1 (en)	1998-08-03	2002-04-30	Insite Vision, Incorporated	Methods of ophthalmic administration
US7083950B2 (en) *	1998-09-25	2006-08-01	Regeneron Pharmaceuticals, Inc.	High affinity fusion proteins and therapeutic and diagnostic methods for use
US6472179B2 (en) *	1998-09-25	2002-10-29	Regeneron Pharmaceuticals, Inc.	Receptor based antagonists and methods of making and using
CA2367375A1 (en)	1999-03-15	2000-09-21	Chiron Corporation	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en)	1999-03-15	2005-09-13	The Regents Of The University Of California	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
KR100659477B1 (ko) *	1999-06-08	2006-12-20	리제네론 파라마큐티칼스 인코포레이티드	개선된 약물동태학적 성질을 가지는 변형된 키메라 폴리펩티드
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
US7070959B1 (en)	1999-06-08	2006-07-04	Regeneron Pharmaceuticals, Inc.	Modified chimeric polypeptides with improved pharmacokinetic properties
US6821775B1 (en)	2000-02-11	2004-11-23	Genvec, Inc.	Viral vector encoding pigment epithelium-derived factor
AU2001292881A1 (en)	2000-09-20	2002-04-02	The Regents Of The University Of California	Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
RU2292904C2 (ru)	2001-01-09	2007-02-10	Мерк Патент Гмбх	Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса
WO2002058615A2 (en) *	2001-01-25	2002-08-01	Hill-Rom Services, Inc.	Hydraulic actuator apparatus for a surgical table
DE10109855A1 (de) *	2001-03-01	2002-09-12	Stanislawski Thomas	Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
US7078411B2 (en) *	2001-05-16	2006-07-18	Umdnj (Univ Of Medicine & Dentist. Of Nj)	Phospholipid transfer protein (PLTP) and cholestoral metabolism
CA2479167A1 (en)	2002-03-20	2003-10-02	University Of Florida Research Foundation, Inc.	Raav vector compositions and methods for the treatment of choroidal neovascularization
CU23178A1 (es)	2002-04-15	2006-09-22	Ct Ingenieria Genetica Biotech	INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
ATE438662T1 (de)	2003-03-26	2009-08-15	Apogenix Gmbh	Verbesserte fc-fusionsproteine
ES2407859T3 (es) *	2004-09-13	2013-06-14	Genzyme Corporation	Construcciones multiméricas.
BRPI0518105A (pt)	2004-12-17	2008-11-04	Genentech Inc	uso de antagonista da angiogênese e uso de anticorpo anti-vegf
WO2010019263A2 (en)	2008-08-15	2010-02-18	Genzyme Corporation	Soluble flt constructs for treating cancers

2005
- 2005-09-13 ES ES10165159T patent/ES2407859T3/es active Active
- 2005-09-13 PL PL05810409T patent/PL1804835T3/pl unknown
- 2005-09-13 JP JP2007531408A patent/JP4944032B2/ja active Active
- 2005-09-13 WO PCT/US2005/032320 patent/WO2006031689A2/en active Application Filing
- 2005-09-13 DE DE602005021811T patent/DE602005021811D1/de active Active
- 2005-09-13 PT PT05810409T patent/PT1804835E/pt unknown
- 2005-09-13 AT AT05810409T patent/ATE470454T1/de active
- 2005-09-13 EP EP05810409A patent/EP1804835B9/de active Active
- 2005-09-13 DK DK05810409.2T patent/DK1804835T3/da active
- 2005-09-13 MX MX2007002942A patent/MX2007002942A/es active IP Right Grant
- 2005-09-13 EP EP10165159.4A patent/EP2229956B1/de active Active
- 2005-09-13 DK DK10165159.4T patent/DK2229956T3/da active
- 2005-09-13 CN CN2005800386237A patent/CN101094688B/zh active Active
- 2005-09-13 PT PT101651594T patent/PT2229956E/pt unknown
- 2005-09-13 PL PL10165159T patent/PL2229956T3/pl unknown
- 2005-09-13 ES ES05810409T patent/ES2347340T3/es active Active
- 2005-09-13 BR BRPI0515264A patent/BRPI0515264B1/pt not_active IP Right Cessation
2007
- 2007-03-11 IL IL181839A patent/IL181839A0/en not_active IP Right Cessation
- 2007-03-12 US US11/716,794 patent/US7928072B2/en active Active
2010
- 2010-12-01 HK HK10111185.0A patent/HK1144663A1/xx not_active IP Right Cessation
2011
- 2011-02-02 US US13/019,432 patent/US8658602B2/en active Active
- 2011-11-01 IL IL216095A patent/IL216095A/en not_active IP Right Cessation
2013
- 2013-07-17 CY CY20131100605T patent/CY1114155T1/el unknown
2014
- 2014-01-31 US US14/170,257 patent/US9815892B2/en active Active
2017
- 2017-10-17 US US15/785,775 patent/US20180155417A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1804835B9 (de)	2010-09-29
EP2229956A1 (de)	2010-09-22
PL2229956T3 (pl)	2013-09-30
PT1804835E (pt)	2010-10-04
BRPI0515264A (pt)	2008-07-15
DK2229956T3 (da)	2013-07-29
DE602005021811D1 (de)	2010-07-22
EP1804835A4 (de)	2008-07-30
EP2229956B1 (de)	2013-04-24
BRPI0515264B1 (pt)	2018-12-18
US20110268735A1 (en)	2011-11-03
US20180155417A1 (en)	2018-06-07
JP4944032B2 (ja)	2012-05-30
PL1804835T3 (pl)	2010-11-30
WO2006031689A2 (en)	2006-03-23
IL181839A0 (en)	2007-07-04
CN101094688A (zh)	2007-12-26
IL216095A0 (en)	2011-12-29
US20140193411A1 (en)	2014-07-10
US8658602B2 (en)	2014-02-25
US20070224178A1 (en)	2007-09-27
US7928072B2 (en)	2011-04-19
EP1804835B1 (de)	2010-06-09
CN101094688B (zh)	2013-05-01
ES2347340T3 (es)	2010-10-28
MX2007002942A (es)	2008-03-05
US9815892B2 (en)	2017-11-14
WO2006031689A3 (en)	2006-07-06
CY1114155T1 (el)	2016-08-31
JP2008512127A (ja)	2008-04-24
DK1804835T3 (da)	2010-10-11
HK1144663A1 (en)	2011-03-04
EP1804835A2 (de)	2007-07-11
IL216095A (en)	2013-10-31
PT2229956E (pt)	2013-07-31
ES2407859T3 (es)	2013-06-14

Publication	Publication Date	Title
ATE470454T1 (de)	2010-06-15	Multimere konstrukte
EA202092093A1 (ru)	2021-06-28	Композиции и способы перепрограммирования tcr с применением слитых белков
Zdanov	2010	Structural analysis of cytokines comprising the IL-10 family
DK2016102T3 (da)	2012-07-02	Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse
MX2021004660A (es)	2021-05-28	Moleculas de union multivalentes a base de igm- e iga-fc.
WO2007097812A3 (en)	2008-07-17	Therapeutic anti-her2 antibody fusion polypeptides
WO2008045437A3 (en)	2008-09-18	Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
PA8738401A1 (es)	2009-02-09	Proteinas de fusion de exendina
ATE475708T1 (de)	2010-08-15	Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion
WO2010003766A3 (en)	2010-04-22	Multimeric tnf receptors
ATE505481T1 (de)	2011-04-15	Fusionsproteine der tnf-superfamilie
CY1119774T1 (el)	2018-06-27	Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2
MX2023001793A (es)	2023-03-10	Ratones que producen proteinas de union que comprenden dominios vl.
WO2010019263A3 (en)	2010-08-12	Soluble flt constructs for treating cancers
DK1532261T3 (da)	2010-05-31	Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte
ATE555383T1 (de)	2012-05-15	Lösliche heterodimere rezeptoren und ihre verwendung
WO2007051063A3 (en)	2009-05-07	Gpcr expressing cell lines and antibodies
WO2010018444A3 (en)	2010-05-14	An expression vector and a method thereof
ATE519784T1 (de)	2011-08-15	An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
Lethbridge et al.	2010	Immunological identification of the mouse H 4 histamine receptor on spinal cord motor neurons using a novel anti-mouse H 4 R antibody
WO2024073513A3 (en)	2024-08-02	Chimeric receptors comprising interleukin 7 receptor (il7r) domains
Tanase et al.	2017	NEW TOOLS FOR DISCOVERING INHIBITORS OF THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS
AR117624A1 (es)	2021-08-18	Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión específicas del blanco
BR112015017778A2 (pt)	2017-11-21	anticorpos que compreendem domínios constantes quiméricos, moléculas de ácido nucleico, vetor, célula e proteína de fusão do receptor fc
PL2164516T3 (pl)	2011-05-31	Zoptymalizowana sekwencja DNA i białkowa przeciwciała do ulepszenia jakości i ilości fuzyjnych białek przeciwciał eksprymowanych w bakteriach

Legal Events

Date	Code	Title	Description
2011-01-15	UEP	Publication of translation of european patent specification	Ref document number: 1804835 Country of ref document: EP

Date

Code

Title

Description

2011-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1804835

Country of ref document: EP